Table 5 Univariate and Multivariate analyses for recurrence-free survival.
From: Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
Risk factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
HRa | P value | 95% CI | HR | P value | 95% CI | |
MEG3 methylation | 3.073 | 0.017 | 1.219~7.746 | 2.619 | 0.045 | 0.979~7.005 |
FIGO stage, (I, II) | 2.405 | 0.032 | 1.078~5.362 | 3.124 | 0.015 | 1.249~7.813 |
Lymph nodes metastasis (Negative, Positive) | 3.243 | 0.005 | 1.418~7.419 | 5.664 | <0.0001 | 2.283~14.052 |
Differentiation (Well/Moderately, Poorly) | 1.581 | 0.264 | 0.708~3.532 | |||
Depth of invasion (≤2/3, >2/3) | 1.124 | 0.775 | 0.503~2.510 | |||
HR HPV infection (Negative, Positive) | 2.404 | 0.155 | 0.717~8.064 | |||
Tumor size | 1.263 | 0.167 | 0.907~1.758 | |||
LVSI (Negative, Positive) | 0.690 | 0.371 | 0.307~1.554 | |||
Age | 1.003 | 0.863 | 0.967~1.040 | |||
Histology (Squamous, Adenocarcinoma) | 1.867 | 0.312 | 0.557~6.260 | |||
Menopause (Yes, No) | 1.444 | 0.370 | 0.647~3.225 | |||
